Merck will encounter some Keytruda-related issues toward the end of the decade, but the company's business and pipeline are ...

Merck will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Merck, a leading global pharmaceutical company that produces a range of medicines, vaccines, and animal healthcare products, ...

Watch out, Eli Lilly and Novo Nordisk. Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs ...

The weight-loss biotech Viking Therapeutics ( VKTX 1.83%) saw its stock get absolutely slammed on Dec. 18, falling 18% as a ...

A Fremont pharmaceutical company received an investment of approximately $50 million — about $3.56 per share — in a private ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...

The company’s $50M investment from Merck (MRK) strengthens its balance sheet with another strategic partner and represents a major derisking event, the analyst tells investors in a research note.

The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...

A Fremont pharmaceutical company received an investment of approximately $50 million in a private placement from Merck & Co.